NCT05548348View on ClinicalTrials.gov

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 26, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

October 31, 2025

Conditions
Non-small Cell Lung CancerEGFR G719XEGFR L861QEGFR S768I
Interventions
DRUG

Furmonertinib 160 mg, Q.D.

Furmonertinib will be administered orally at a dose of 160 mg per time, Q.D.

Trial Locations (3)

400010

RECRUITING

The Second Affilicated Hospital of Chongqing Medical University, Chongqing

400030

RECRUITING

Chongqing University Cancer Hospital, Chongqing

400042

RECRUITING

Army Specialty Medical Center, Chongqing

All Listed Sponsors
collaborator

Army Specialty Medical Center

UNKNOWN

collaborator

The Second Affilicated Hospital of Chongqing Medical University

UNKNOWN

lead

Chongqing University Cancer Hospital

OTHER